Treatment of acromegaly patients at the Federal University of Triângulo Mineiro (UFTM): Experience Report

Borges, Maria de Fátima; Lara, Beatriz Hallal Jorge; Tomé, Janaíne Machado; Araújo, Leopoldo Prézia de; Bugiga, Flávio Cesar Lucas; Sousa, Júlio Cláudio; Soares, Jacqueline Mendes Fonseca; Dezena, Roberto Alexandre; Ferreira, Béatriz

doi:10.6061/clinics/2017(04)05

Cited by 2 publications

(1 citation statement)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a study carried out at the Clinical Hospital of the Federal University of Triângulo Mineiro, 12.4% of the patients evaluated presented arterial hypertension, indicating the need for a specific approach of the cardiovascular system in acromegalics, motivating a more in-depth observation of the cardiovascular complications in these patients in our clinic (Borges et al, 2017).…”

Section: Introductionmentioning

confidence: 99%

Cardiac Structural Alterations of Acromegalic, Without Alteration in Cardiac Function, Evaluated by Doppler Echocardiography with Speckle Tracking

Oliveira¹,

Lara²,

Tomé³

et al. 2021

GJHS

Self Cite

View full text Add to dashboard Cite

BACKGROUND: Acromegaly is most commonly caused by growth hormone secreting pituitary (GH) macroadenoma. Cardiovascular events are the leading cause of death in this population. OBJECTIVE: To analyze the cardiac structural and functional changes in patients with acromegaly and to correlate the findings with the concentrations of GH and IGF-1 post treatment and with the presumed time of disease. METHOD: A quantitative study involving 19 individuals with acromegaly, 10 with inactive disease and 9 with active disease and 16 healthy individuals, matched by sex and age. Age ranged from 19 to 78 years. Two-dimensional echocardiogram and speckle tracking were performed. RESULTS: Mean left ventricular mass index (LVMI) were significantly higher in acromegalic patients (89.1 ± 27.9) compared to the control group (66.9 ± 15.7) (p = 0.015). There was a direct correlation between IGF-1 mean concentration and left ventricular systolic volume (LVSV) in acromegalic patients (r = 0.64; p = 0.004) even when the disease was inactive (n=10; r = 0.9; p = 0.002) and between IGF1 mean concentration and left ventricular diastolic volume (LVDV). The left ventricular ejection fraction (EF) and the global longitudinal strain (GLS) did not differ between groups (p> 0.05). CONCLUSION: Although patients with acromegaly had higher LVMI, they did not show difference in GLS indicating a small chance of progression to systolic disfunction. Direct correlation between IGF-1 and LDVD and LVSV demonstrates the relevance of a good hormonal control to reduce cardiac changes.

show abstract

Section: Introductionmentioning

confidence: 99%

Cardiac Structural Alterations of Acromegalic, Without Alteration in Cardiac Function, Evaluated by Doppler Echocardiography with Speckle Tracking

Oliveira¹,

Lara²,

Tomé³

et al. 2021

GJHS

Self Cite

View full text Add to dashboard Cite

show abstract

How are growth hormone and insulin-like growth factor-1 reported as markers for drug effectiveness in clinical acromegaly research? A comprehensive methodologic review

et al. 2018

View full text Add to dashboard Cite

ObjectiveIn rare disease research, most randomized prospective clinical trials can only use limited number of patients and are comprised of highly heterogeneous populations. Therefore, it is crucial to report the results in such a manner that it allows for comparison of treatment effectiveness and biochemical control between studies. The aim of this review was to investigate the current methods that are being applied to measure and report growth hormone (GH) and insulin-like growth factor-1 (IGF-1) as markers for drug effectiveness in clinical acromegaly research.Search strategyA systematic search of recent prospective and retrospective studies, published between 2012 and 2017, that studied the effects of somatostatin analogues or dopamine agonists in acromegaly patients was performed. The markers of interest were GH, IGF-1, and the suppression of GH after an oral glucose tolerance test (OGTT). Additionally, the use of pharmacokinetic (PK) measurements in these studies was analyzed. The sampling design, cut-off for biochemical control, reported units, and used summary statistics were summarized.ResultsA total of 49 articles were selected out of the 263 screened abstracts. IGF-1 concentrations were measured in all 49 studies, GH in 45 studies, and an OGTT was performed in 11 studies. A wide range of different cut-off values and sampling designs were used to determine biochemical control in acromegaly patients. The summary statistics were reported in various ways, with the percentage of biochemical control most frequently used. Nine studies sampled the PK at one or more time points. Non-compartmental analyses were commonly performed on the available PK data.ConclusionsThe way GH and IGF-1 are measured and reported in acromegaly research varies considerably. A consensus on how to report study results would enable better comparisons between studies, thereby improving evidence based decision making to optimize treatment in acromegaly.Electronic supplementary materialThe online version of this article (10.1007/s11102-018-0884-4) contains supplementary material, which is available to authorized users.

show abstract

Treatment of acromegaly patients at the Federal University of Triângulo Mineiro (UFTM): Experience Report

Cited by 2 publications

References 29 publications

Cardiac Structural Alterations of Acromegalic, Without Alteration in Cardiac Function, Evaluated by Doppler Echocardiography with Speckle Tracking

Cardiac Structural Alterations of Acromegalic, Without Alteration in Cardiac Function, Evaluated by Doppler Echocardiography with Speckle Tracking

How are growth hormone and insulin-like growth factor-1 reported as markers for drug effectiveness in clinical acromegaly research? A comprehensive methodologic review

Contact Info

Product

Resources

About